BR112013033974A2 - terapia de combinação - Google Patents

terapia de combinação

Info

Publication number
BR112013033974A2
BR112013033974A2 BR112013033974A BR112013033974A BR112013033974A2 BR 112013033974 A2 BR112013033974 A2 BR 112013033974A2 BR 112013033974 A BR112013033974 A BR 112013033974A BR 112013033974 A BR112013033974 A BR 112013033974A BR 112013033974 A2 BR112013033974 A2 BR 112013033974A2
Authority
BR
Brazil
Prior art keywords
combination therapy
therapy
combination
Prior art date
Application number
BR112013033974A
Other languages
English (en)
Inventor
Gidley-Baird Angus
Barden Julian
Original Assignee
Biosceptre Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011902623A external-priority patent/AU2011902623A0/en
Application filed by Biosceptre Int Ltd filed Critical Biosceptre Int Ltd
Publication of BR112013033974A2 publication Critical patent/BR112013033974A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013033974A 2011-07-01 2012-07-02 terapia de combinação BR112013033974A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2011902623A AU2011902623A0 (en) 2011-07-01 Combination therapy
PCT/AU2012/000795 WO2013003895A1 (en) 2011-07-01 2012-07-02 Combination therapy

Publications (1)

Publication Number Publication Date
BR112013033974A2 true BR112013033974A2 (pt) 2017-02-14

Family

ID=47436374

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013033974A BR112013033974A2 (pt) 2011-07-01 2012-07-02 terapia de combinação

Country Status (11)

Country Link
US (3) US9566318B2 (pt)
EP (1) EP2726095B1 (pt)
JP (2) JP6305920B2 (pt)
CN (1) CN103702683B (pt)
AU (1) AU2012278921B2 (pt)
BR (1) BR112013033974A2 (pt)
CA (1) CA2840251C (pt)
ES (1) ES2689272T3 (pt)
MX (1) MX349321B (pt)
WO (1) WO2013003895A1 (pt)
ZA (1) ZA201400120B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319011B (en) 2001-01-17 2010-01-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
WO2009033233A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Novel p2x7 epitopes
CN102143978B (zh) 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
EP2966090B1 (en) 2009-08-20 2018-10-10 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
CA2784345C (en) 2009-12-24 2018-11-13 Julian Alexander Barden Antibodies to non-functional oligomeric p2x7 receptors
ES2656971T3 (es) 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
US8846107B2 (en) 2010-12-29 2014-09-30 Ecolab Usa Inc. In situ generation of peroxycarboxylic acids at alkaline pH, and methods of use thereof
US8933263B2 (en) 2010-12-29 2015-01-13 Ecolab Usa Inc. Water temperature as a means of controlling kinetics of onsite generated peracids
ES2689272T3 (es) 2011-07-01 2018-11-13 Biosceptre (Aust) Pty Ltd Terapia de combinación
US9321664B2 (en) 2011-12-20 2016-04-26 Ecolab Usa Inc. Stable percarboxylic acid compositions and uses thereof
MY191132A (en) 2014-12-18 2022-05-31 Ecolab Usa Inc Generation of peroxyformic acid through polyhydric alcohol formate
EP3232781A4 (en) 2014-12-18 2018-08-22 Ecolab USA Inc. Methods for forming peroxyformic acid and uses thereof
US11040902B2 (en) 2014-12-18 2021-06-22 Ecolab Usa Inc. Use of percarboxylic acids for scale prevention in treatment systems
MX2019004410A (es) * 2016-10-21 2019-09-26 Biosceptre Uk Ltd Particulas citotoxicas.
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
US5500161A (en) 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
JPH10501122A (ja) 1994-05-27 1998-02-03 グラクソ、グループ、リミテッド Ｐ▲下２ｘ▼レセプター（プリノセプターファミリー）
EP0854923A2 (en) 1995-08-09 1998-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
EP0907729A1 (en) 1996-04-30 1999-04-14 Smithkline Beecham Plc HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
EP2080802B1 (en) 1998-06-01 2017-03-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
NL1012452C2 (nl) 1999-06-28 2001-01-02 Univ Delft Tech Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten.
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
WO2003020762A1 (en) 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
TWI319011B (en) * 2001-01-17 2010-01-01 Intreat Pty Ltd Diagnosis and treatment of cancers and other conditions
JP2006523648A (ja) 2003-04-17 2006-10-19 アフェクティス ファーマシューティカルズ アーゲー 情動障害の診断および治療のための手段および方法
CA2993042A1 (en) * 2004-01-23 2005-08-04 Msd Italia S.R.L. Chimpanzee adenovirus vaccine carriers
US7858323B2 (en) * 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
GB0419295D0 (en) * 2004-08-31 2004-09-29 Genomica Sau Methods and compositions to prevent neuronal degeneration
WO2006136004A1 (en) 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
EP1929305A2 (en) 2005-08-31 2008-06-11 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
US20100036101A1 (en) 2006-10-10 2010-02-11 Angus Gidley-Baird Antibodies against non functional p2x7 receptor
AU2007306924A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Hybridomas producing antibodies against non functional P2X7 receptor
WO2009033233A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Novel p2x7 epitopes
WO2009033234A1 (en) 2007-09-14 2009-03-19 Biosceptre International Limited Purinergic (p2x) receptors in extra-cellular body fluid
CN102143978B (zh) * 2008-07-04 2015-02-18 生物权威国际有限公司 抗p2x7肽和表位
BR122021010546B1 (pt) * 2008-12-10 2022-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc Uso de uma composição com uma quantidade eficaz de um peptídeo gp2 e de gm-csf
EP2966090B1 (en) 2009-08-20 2018-10-10 Biosceptre (Aust) Pty Ltd Anti p2x7 receptor antibodies and fragments thereof
CA2784345C (en) * 2009-12-24 2018-11-13 Julian Alexander Barden Antibodies to non-functional oligomeric p2x7 receptors
WO2011131472A1 (en) 2010-04-22 2011-10-27 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
ES2656971T3 (es) * 2010-09-10 2018-03-01 Biosceptre (Aust) Pty Ltd Tratamientos para el cáncer en animales de compañía con un anticuerpo anti P2X7
ES2689272T3 (es) 2011-07-01 2018-11-13 Biosceptre (Aust) Pty Ltd Terapia de combinación

Also Published As

Publication number Publication date
JP2018087249A (ja) 2018-06-07
US20150004179A1 (en) 2015-01-01
US20170157229A1 (en) 2017-06-08
JP6490270B2 (ja) 2019-03-27
US10543262B2 (en) 2020-01-28
CA2840251C (en) 2023-09-12
AU2012278921B2 (en) 2016-11-10
EP2726095B1 (en) 2018-06-06
ZA201400120B (en) 2015-09-30
EP2726095A4 (en) 2015-01-07
CA2840251A1 (en) 2013-01-10
US20190224290A1 (en) 2019-07-25
CN103702683A (zh) 2014-04-02
CN103702683B (zh) 2017-07-04
AU2012278921A1 (en) 2014-01-16
MX349321B (es) 2017-07-21
US9566318B2 (en) 2017-02-14
JP2014520759A (ja) 2014-08-25
ES2689272T3 (es) 2018-11-13
WO2013003895A1 (en) 2013-01-10
JP6305920B2 (ja) 2018-04-04
US10245308B2 (en) 2019-04-02
EP2726095A1 (en) 2014-05-07
MX2014000199A (es) 2014-06-11

Similar Documents

Publication Publication Date Title
DK2744810T4 (da) Tenofovir-alafenamid-hemifumarat
BR112013033974A2 (pt) terapia de combinação
DK2760886T3 (da) Immunocytokin-kombinationsterapi
DK2769050T3 (da) Propsensor
BR112014000879A2 (pt) deflegmador
FI20115876A0 (fi) Yhdistelmähoito
DK3272861T3 (da) Alpha-galactosidase-sammensætninger
CO6960543A2 (es) 2-tiopirimidinonas
DE102011100082A8 (de) Traygreifvorrichtung
DK3141251T3 (da) Koloskopi - forberedelse
BR112014000742A2 (pt) terapia de combinação de als
CO6880064A2 (es) Métodos terapéuticos
DE112011104936A5 (de) Stanzstauchniet
FI20115640A0 (fi) Yhdistelmähoito
DE112012000958A5 (de) Handsäge
DK2476953T3 (da) Fluidbedkedel
DE112012002458A5 (de) Hydrotransformator
DK2694056T3 (da) Terapeutisk behandling
DE112012000819A5 (de) Gurtbandfänger
DE112012005313A5 (de) Leuchtbild
DK2526750T3 (da) Høbjærgningsmaskine
DE112012001294T8 (de) Umspritzungsverfahren
DE102011117169A8 (de) Absetzplattenanordnung
DE112011105396A5 (de) Nachverfestigungsverfahren
DK2663304T3 (da) Kombinationsterapi

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL